참고문헌

참고문헌

  1. NeuroStar Prescribing Information.
  2. World Health Organization. Depression fact sheet No.369. http://www.who.int/mediacentre/factsheets/fs369/en/index.html. Accessed February 27, 2013.
  3. World Health Organization. The global burden of disease: 2004 update. http://www.who.int/healthinfo/global_burden_disease/2004_report_update/en/index.html. Accessed March 12, 2013.
  4. Stahl SM. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 3rd ed. New York, NY: Cambridge University Press (2008).
  5. Janicak PG, et al. (2008). Transcranial magnetic stimulation in the treatment of major depressive disorder: a comprehensive summary of safety experience from acute exposure, extended exposure, and during reintroduction treatment. J Clin Psychiatry, 69(2):222-232.
  6. Data on file. Neuronetics, Inc.
  7. O’Reardon JP, et al. (2007). Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry, 62(11):1208-1216.
  8. George MS, et al. (2010). Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. Arch Gen Psychiatry, 67(5):507-516.
  9. Carpenter LL, et al. (2012). Transcranial magnetic stimulation (TMS) for major depression: a multisite naturalistc, observational study of acute treatment outcomes in clinical practice. Depress Anxiety, 29(7):587-596.
  10. Avery DH, et al. (2008). Transcranial Magnetic Stimulation in the acute treatment of major depressive disorder: clinical response in an open-label extension trial. J Clin Psychiatry, 69(3):441-451.
  11. McDonald WM, et al. (2011). Improving the antidepressant efficacy of transcranial magnetic stimulation: maximizing the number of stimulations and treatment location in treatment-resistant depression. Depress Anxiety, 28(11):973-980.
  12. Janicak PG, et al. (2010). Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: assessment of relapse during a 6-month, multisite, open-label study. Brain Stimulation, 3(4):187-199.
  13. Demitrack MA, Thase ME. (2009). Clinical significance of transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant depression: synthesis of recent data. Psychopharmacol Bull, 42(2):5-38.
  14. Liston C, et al. (2014) Default Mode Network Mechanisms of Transcranial Magnetic Stimulation in Depression. Biol. Psychiatry 76(7): 517–526
  15. World Health Organization. The World Health Report 2001: Mental Health: New Understanding, New Hope. www.who.int/whr/2001/en/whr01_en.pdf. Accessed March 12, 2013.
  16. Kessler, RC et al. (2003). Epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA, 289:3095-3105.
  17. World Health Organization. The ICD-10 classifications of mental and behavioral disorders: clinical descriptions and diagnostic guidelines. www.who.int/classifications/icd/en/bluebook.pdf. Accessed March 12, 2013.
  18. Sackeim HA, et al. (2020). Clinical Outcomes in a Large Registry of Patients with Major Depressive Disorder Treated with Transcranial Magnetic Stimulation. J Affective Disorders, 277(12):65-74.
  19. Carpenter, LL, et al. (2021). Comparison of Clinical Outcomes with Two Transcranial Magnetic Stimulation Treatment Protocols for Major Depressive Disorder. Brain Stim, 14(1): 173-180.
  20. Dunner DL, et al. (2014) A Multisite, Naturalistic, Observational Study of Transcranial Magnetic Stimulation (TMS) for Patients with Pharmacoresistant Major Depression: Durability of Benefit Over a One-Year Follow-Up Period. J Clin Psych, 75(12):1394-1401.
  21. Mantovani A, et al. (2012). Long-Term Efficacy of Repeated Daily Prefrontal Transcranial Magnetic Stimulation (TMS) in Treatment-Resistant Depression. Depress Anxiety, 29 (10):883-890.

1. NeuroStar Prescribing Information.

2. World Health Organization. Depression fact sheet No.369. LINK. Accessed February 27, 2013.

3. World Health Organization. The global burden of disease: 2004 update. LINK. Accessed March 12, 2013.

4. Stahl SM. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 3rd ed. New York, NY: Cambridge University Press (2008).

5. Janicak PG, et al. (2008). Transcranial magnetic stimulation in the treatment of major depressive disorder: a comprehensive summary of safety experience from acute exposure, extended exposure, and during reintroduction treatment. J Clin Psychiatry, 69(2):222-232.

6. Data on file. Neuronetics, Inc.

7. O’Reardon JP, et al. (2007). Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry, 62(11):1208-1216.

8. George MS, et al. (2010). Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. Arch Gen Psychiatry, 67(5):507-516.

9. Carpenter LL, et al. (2012). Transcranial magnetic stimulation (TMS) for major depression: a multisite naturalistc, observational study of acute treatment outcomes in clinical practice. Depress Anxiety, 29(7):587-596.

10. Avery DH, et al. (2008). Transcranial Magnetic Stimulation in the acute treatment of major depressive disorder: clinical response in an open-label extension trial. J Clin Psychiatry, 69(3):441-451.

11. McDonald WM, et al. (2011). Improving the antidepressant efficacy of transcranial magnetic stimulation: maximizing the number of stimulations and treatment location in treatment-resistant depression. Depress Anxiety, 28(11):973-980.

12. Janicak PG, et al. (2010). Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: assessment of relapse during a 6-month, multisite, open-label study. Brain Stimulation, 3(4):187-199.

13. Demitrack MA, Thase ME. (2009). Clinical significance of transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant depression: synthesis of recent data. Psychopharmacol Bull, 42(2):5-38.

14. Liston C, et al. (2014) Default Mode Network Mechanisms of Transcranial Magnetic Stimulation in Depression. Biol. Psychiatry 76(7): 517–526

15. World Health Organization. The World Health Report 2001: Mental Health: New Understanding, New Hope. LINK. Accessed March 12, 2013.

16. Kessler, RC et al. (2003). Epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA, 289:3095-3105.

17. World Health Organization. The ICD-10 classifications of mental and behavioral disorders: clinical descriptions and diagnostic guidelines. LINK. Accessed March 12, 2013.

18. Sackeim HA, et al. (2020). Clinical Outcomes in a Large Registry of Patients with Major Depressive Disorder Treated with Transcranial Magnetic Stimulation. J Affective Disorders, 277(12):65-74.

19. Carpenter, LL, et al. (2021). Comparison of Clinical Outcomes with Two Transcranial Magnetic Stimulation Treatment Protocols for Major Depressive Disorder. Brain Stim, 14(1): 173-180.

20. Dunner DL, et al. (2014) A Multisite, Naturalistic, Observational Study of Transcranial Magnetic Stimulation (TMS) for Patients with Pharmacoresistant Major Depression: Durability of Benefit Over a One-Year Follow-Up Period. J Clin Psych, 75(12):1394-1401.

21. Mantovani A, et al. (2012). Long-Term Efficacy of Repeated Daily Prefrontal Transcranial Magnetic Stimulation (TMS) in Treatment-Resistant Depression. Depress Anxiety, 29 (10):883-890.

이 웹사이트에 포함된 정보는 미국을 제외한 해외 시장만을 대상으로 합니다.

적용
NeuroStar TMS Therapy는 주요우울장애(MDD)를 앓고 있으면서 항우울제로 만족스러운 효과를 보지 못하는 성인 환자를 위한 치료법입니다.

NeuroStar TMS Therapy는 의사 처방이 있어야만 사용 가능합니다. 의사는 NeuroStar TMS Therapy가 당신에게 적합한지 결정하는 것을 도울 수 있습니다.

중요 안전 정보
NeuroStar TMS Therapy는 두개골 내부나 주변에 제거가 불가능한 전도성 금속이 있는 환자에게 사용해서는 안됩니다.

이전에 항우울제 치료를 받지 않은 환자를 대상으로는 NeuroStar TMS Therapy가 연구된 바 없습니다.

가장 흔한 부작용은 치료 부위나 그 주변 부위의 통증이나 불편감입니다. NeuroStar TMS 사용과 관련하여 발작의 위험은 거의 없습니다(환자당< 0.1%미만). TMS Therapy가 자신에게 적합한지 판단하려면 NeuroStar 의사와 상담해야 합니다.

저작권 @ 2024 Neuronetics. All Rights Reserved.

Twitter Youtube